Anemia with Elevation of Growth Differentiation Factor-15 Level in Linezolid Treated Multidrug-resistant Tuberculosis: Case Series of Three Patients

Overview

Journal IDCases

Specialty Infectious Diseases

Date 2022 Aug 12

PMID 35957807

Authors

Amaylia Oehadian

Prayudi Santoso

Dick Menzies

Rovina Ruslami

Affiliations

Soon will be listed here.

Abstract

Linezolid is now recommended as a first line drug for Multidrug Resistant Tuberculosis (MDR-TB). Previous studies reported hematologic toxicity as one of the main side effects. The mechanism of this toxicity is mitochondrial dysfunction, for which a biomarker is Growth differentiation factor-15 (GDF-15). There is no previous report about GDF-15 and its association with hematologic toxicity from Linezolid in the treatment of MDR-TB. We present three cases of MDR-TB involving severe anemia associated with linezolid who had GDF-15 elevation. These cases highlight the need for more research into the relationship between GDF-15 and hematologic toxicity in MDR-TB patients treated with linezolid.

References

Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, Ito M . Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int. 2016; 16 Suppl 1:17-29. DOI: 10.1111/ggi.12724. View

Leach K, Swaney S, Colca J, McDonald W, Blinn J, Thomasco L . The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007; 26(3):393-402. DOI: 10.1016/j.molcel.2007.04.005. View

Garrabou G, Soriano A, Lopez S, Guallar J, Giralt M, Villarroya F . Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother. 2006; 51(3):962-7. PMC: 1803121. DOI: 10.1128/AAC.01190-06. View

Mann T, Davis J, Walzl G, Beltran C, Du Toit J, Lamberts R . Candidate Biomarkers to Distinguish Spinal Tuberculosis From Mechanical Back Pain in a Tuberculosis Endemic Setting. Front Immunol. 2021; 12:768040. PMC: 8637108. DOI: 10.3389/fimmu.2021.768040. View

Sotgiu G, Centis R, DAmbrosio L, Alffenaar J, Anger H, Caminero J . Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012; 40(6):1430-42. DOI: 10.1183/09031936.00022912. View

Banaszkiewicz M, Malyszko J, Batko K, Koc-Zorawska E, Zorawski M, Dumnicka P . Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma. Mediators Inflamm. 2020; 2020:5657864. PMC: 7596430. DOI: 10.1155/2020/5657864. View

Liu X, Chi X, Gong Q, Gao L, Niu Y, Chi X . Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma. PLoS One. 2015; 10(5):e0127518. PMC: 4440744. DOI: 10.1371/journal.pone.0127518. View

Welsh J, Sapinoso L, Kern S, Brown D, Liu T, Bauskin A . Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003; 100(6):3410-5. PMC: 152306. DOI: 10.1073/pnas.0530278100. View

Theurl I, Finkenstedt A, Schroll A, Nairz M, Sonnweber T, Bellmann-Weiler R . Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol. 2009; 148(3):449-55. DOI: 10.1111/j.1365-2141.2009.07961.x. View

10.

Nalado A, Olorunfemi G, Dix-Peek T, Dickens C, Khambule L, Snyman T . Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol. 2020; 21(1):415. PMC: 7523312. DOI: 10.1186/s12882-020-02046-7. View

11.

Przybylowski P, Wasilewski G, Bachorzewska-Gajewska H, Golabek K, Dobrzycki S, Malyszko J . Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure. Transplant Proc. 2014; 46(8):2852-5. DOI: 10.1016/j.transproceed.2014.09.040. View

12.

Soriano A, Miro O, Mensa J . Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005; 353(21):2305-6. DOI: 10.1056/NEJM200511243532123. View

13.

Ueland T, Gullestad L, Kou L, Young J, Pfeffer M, van Veldhuisen D . Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. Clin Res Cardiol. 2021; 111(4):440-450. PMC: 8971146. DOI: 10.1007/s00392-021-01944-6. View

14.

Leader R, Hackett J, Allan A, Carter P . Linezolid-induced pancytopenia. BMJ Case Rep. 2018; 2018. PMC: 6067138. DOI: 10.1136/bcr-2018-225480. View

15.

Wollert K, Kempf T, Wallentin L . Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. Clin Chem. 2017; 63(1):140-151. DOI: 10.1373/clinchem.2016.255174. View

16.

Shi Y, Massague J . Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. DOI: 10.1016/s0092-8674(03)00432-x. View

17.

Ago T, Sadoshima J . GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006; 98(3):294-7. DOI: 10.1161/01.RES.0000207919.83894.9d. View

18.

Behar S, Martin C, Booty M, Nishimura T, Zhao X, Gan H . Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunol. 2011; 4(3):279-87. PMC: 3155700. DOI: 10.1038/mi.2011.3. View

19.

Tanno T, Noel P, Miller J . Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010; 17(3):184-90. PMC: 2884377. DOI: 10.1097/MOH.0b013e328337b52f. View

20.

Fine-Coulson K, Giguere S, Quinn F, Reaves B . Infection of A549 human type II epithelial cells with Mycobacterium tuberculosis induces changes in mitochondrial morphology, distribution and mass that are dependent on the early secreted antigen, ESAT-6. Microbes Infect. 2015; 17(10):689-97. DOI: 10.1016/j.micinf.2015.06.003. View